AI assistant
Rapport Therapeutics, Inc. — Director's Dealing 2025
Oct 16, 2025
32034_dirs_2025-10-16_31cff9fc-f8ee-477a-a1c7-9b229a92341d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Rapport Therapeutics, Inc. (RAPP)
CIK: 0002012593
Period of Report: 2025-10-15
Reporting Person: Ceesay Abraham (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-10-15 | Common Stock | S | 4647 | $25.724 | Disposed | 580765 | Direct |
| 2025-10-15 | Common Stock | S | 1186 | $26.1392 | Disposed | 579579 | Direct |
| 2025-10-15 | Common Stock | S | 4328 | $25.746 | Disposed | 41816 | Indirect |
| 2025-10-15 | Common Stock | S | 755 | $26.1721 | Disposed | 41061 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 81729 | Indirect |
Footnotes
F1: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.06 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.06 to $26.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.07 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F5: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.08 to $26.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F7: Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.